Skip to main content
SPRY
NASDAQ Life Sciences

ARS Pharma Q3 Revenue $37.7M, Net Loss Narrows to $35.6M; Breakeven Target Reaffirmed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2.65
Mkt Cap
$263.535M
52W Low
$2.59
52W High
$13.15
52W Position info
2.3% above low
Off High info
80% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

SPRY is trading near its 52-week low of $2.59 (2.3% above the low).

Summary

ARS Pharma reported Q3 2026 revenue of $37.7M and a narrowed net loss of $35.6M, with SG&A down sharply and cash flow breakeven still targeted for year-end 2027.


Key Events · Earnings and Guidance · SPRY

  • Q3 Revenue Grows to $37.7M

    Total revenue was $37.7M versus $32.5M a year earlier, including $33.4M of U.S. net product revenue for neffy.

  • Net Loss Narrows on Cost Cuts

    Net loss fell to $35.6M, or $(0.36) per share, from $51.2M, or $(0.52) per share, as SG&A dropped to $43.5M from $74.8M.

  • Market Share Still Modest

    Total U.S. neffy market share reached 5%, up from 4%, and about 9% in field-targeted accounts versus 2% in non-targeted accounts.

  • Breakeven Target Reaffirmed

    With $138.4M in cash, cash equivalents and short-term investments at September 30, 2026, the company still expects cash flow breakeven by the end of 2027.


Analysis · SPRY · Life Sciences

Revenue grew to $37.7M from $32.5M a year ago, but the more important number is on the cost side: SG&A fell to $43.5M from $74.8M after the company pulled back on linear TV and broad consumer advertising. That cut the quarterly net loss to $35.6M from $51.2M and keeps management's year-end 2027 cash flow breakeven target intact on $138.4M of cash and short-term investments. The offset is growth: neffy's total U.S. market share is only 5%, up from 4% a year ago, and the new commercial chief is shifting to account-based targeting. With the stock near its 52-week low of $2.59, the market is already pricing skepticism about the growth story; cost discipline is what protects the runway while that strategy is tested.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SPRY was trading at $2.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $263.5M. The 52-week trading range was $2.59 to $13.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SPRY - Latest Insights

SPRY
Nov 05, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.65
Real-time Price: $3.56 info
Change: +$0.910 (+34%) info
Market Cap: $358.886M info
SPRY
Nov 05, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.65
Real-time Price: $3.56 info
Change: +$0.910 (+34%) info
Market Cap: $358.886M info
SPRY
Aug 13, 2026, 4:13 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $5.31
Real-time Price: $3.56 info
Change: -$1.75 (-33%) info
Market Cap: $358.886M info
SPRY
Aug 13, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.32
Real-time Price: $3.56 info
Change: -$1.76 (-33%) info
Market Cap: $358.886M info
SPRY
Aug 13, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.12
Real-time Price: $3.56 info
Change: -$1.56 (-30%) info
Market Cap: $358.886M info